Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2003
08/07/2003WO2003011873A8 Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
08/07/2003WO2003009835A3 Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
08/07/2003WO2003004034B1 Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
08/07/2003WO2002068476A3 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
08/07/2003WO2002059363A3 Method for detecting of prions in a sample
08/07/2003WO2002055541A3 Peptides having inhibiting activity on the production of nitric oxide
08/07/2003WO2002048150A3 Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
08/07/2003WO2002024222A3 Ligands for g protein coupled receptors and methods of using them
08/07/2003WO2002009709A8 Method for reducing or eliminating smoking
08/07/2003WO2002000172A3 Methods for using tetanus toxin for benificial purposes in animals (mammals)
08/07/2003US20030149998 Nucleotide sequences coding orphan receptors/membrane proteins OM-10 and UP-11 for detecting modulators of inflammation, nervous system activity and infection; antitumor/antiinflammatory agents; gene expression inhibition
08/07/2003US20030149277 Triarylimidazole derivatives as cytokine inhibitors
08/07/2003US20030149269 Substituted piperidine derivatives
08/07/2003US20030149250 Labeled compounds useful in imaging amyloid deposits and useful for inhibiting the aggregation of amyloid protein to form amyloid deposit
08/07/2003US20030149237 G-protein coupled receptor for treatment and prevention of eating, cancer, autoimmune, vision and nervous sytem disorders; antiinflammatory agents
08/07/2003US20030149110 For use as as neuro-protective agents for therapy of conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine
08/07/2003US20030149108 Linked biaryl compounds
08/07/2003US20030149107 For therapy of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis
08/07/2003US20030149094 Compositions comprising ether compounds and pharmaceutical uses therefor
08/07/2003US20030149091 For therapy of inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder
08/07/2003US20030149081 For therapy and prophylaxis of asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, inflammatory bowel disease, atherosclerosis
08/07/2003US20030149067 Crystallisation of the desired crystalline form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals
08/07/2003US20030149066 Administering nalbuphine or a prodrug of nalbuphine, and an opioid antagonist selected from the group consisting of naloxone, naltrexone, nalmefene, pharmaceutically acceptable salts thereof or prodrugs
08/07/2003US20030149065 Arylkylamine spirofuropyridines useful in therapy
08/07/2003US20030149060 A2A adenosine receptor antagonists
08/07/2003US20030149059 Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
08/07/2003US20030149058 Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
08/07/2003US20030149051 For therapy of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, cancer, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks
08/07/2003US20030149047 Novel compounds
08/07/2003US20030149046 Pyrazoline derivative or tetrahydropyridazine derivative and medicinal use thereof
08/07/2003US20030149044 Succinic acid salts of 5,7,14-triazatetracyclo[10.1.02.11.04,9] -hexadeca-1(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
08/07/2003US20030149039 For therapy of disease responsive to antagonist modulation of the Neurokinin-1 (NK-1) receptor in a patient
08/07/2003US20030149037 For therapy and prophylaxis of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, etc.
08/07/2003US20030149036 Substituted benzothiazole amide derivatives
08/07/2003US20030149033 For prophylaxis and therapy of cerebrovascular diseases such as cerebral ischemia, stroke, reperfusion damage, brain trauma, edemas, cerebral thrombosis, dementia and Alzheimer's diseass
08/07/2003US20030149030 7-phenyl-benzo [b] thiophen amide derivatives
08/07/2003US20030149026 For therapy of arthritis, fever, common cold, dysmenorrhea, menstrual cramps, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, bronchitis, chronic obstructive pulmonary disease, etc.
08/07/2003US20030149024 For therapy of central nervous system disorders such as diseases and conditions related to sleeping, eating, perceiving pain, controlling body temperature, controlling blood pressure, depression, anxiety, schizophrenia
08/07/2003US20030149023 Novel compounds with analgesic effect
08/07/2003US20030149018 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
08/07/2003US20030149010 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
08/07/2003US20030149007 For inducing bronchodilation or providing relief of bronchospasm
08/07/2003US20030149006 New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents
08/07/2003US20030149001 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
08/07/2003US20030148991 Use of at least one lipoic acid, of a physiologically acceptable derivative and/or salt thereof and at least one C1 donor for producing formulation for C1 donor-assisted therapy of central nervous system disorders
08/07/2003US20030148983 Polynucleotide therapy
08/07/2003US20030148961 Peptidyl ketones as inhibitors of DPIV
08/07/2003US20030148947 MIP as a research tool for identification, characterization and purification of molecules involved in cellular transport and osmotic regulation; agonists/antagonists; vision defects; anitinflammatory agents; nervous system and kidney disorders
08/07/2003US20030148945 Antimicrobial and anti-inflammatory peptides
08/07/2003US20030148941 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
08/07/2003US20030148934 Human growth factor modulators (GFMO) polynucleotides which identify and encode GFMO; amino acid sequences, expression vectors, host cells, antibodies, agonists, and antagonists; anticarcinogenic agents; fibrotic disorders
08/07/2003US20030148513 Preparing culture of pluripotent brain tissue for nervous tissue regeneration, tissue engineering and treating nervous system disorders
08/07/2003US20030148446 Acute neuronal induced calcium binding protein type 1 ligand
08/07/2003US20030148394 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058, or 6351 molecules
08/07/2003US20030148382 PanCAM nucleic acids and polypeptides
08/07/2003US20030148323 Analyzing nucleic acid and determining presence of mutant alleles encoding a protein with reduced activity/thermal stability; useful in diagnosing schizophrenia
08/07/2003US20030148274 Identification of neural defects associated with the nucleosomal assembly protein 112 gene
08/07/2003US20030148264 PDZ (PSD-95/Discs large/ZO-I) domains, (PSD-95 = post-synaptic density protein-95); PDZ proteins involved in assembling ion channels and other transmembrane receptors, at specialized subcellular sites such as tight junctions
08/07/2003US20030147967 Apparatus and method for preparing microparticles
08/07/2003US20030147957 An inner core formulated for controlled release comprising a mixture of a granulated admixture of a decarboxylase inhibitor and a surfactant, and levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof;immediate release
08/07/2003US20030147937 Di-myo-inositol phosphate, cyclic 2,3 diphosphoglycerate, 1,1-di- glycerol phosphate, mannosylglycerate, mannosyl glyceramide and/or di-mannosyl-di-inositol phosphate; protecting organisms, organs, tissues, cells from oxidation
08/07/2003US20030147903 ABC transport polynucleotides, polypeptides and antibodies
08/07/2003US20030147889 Administering type 1-interferon antibody, for inhibition of prevention of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, multiple sclerosis and psoriasis
08/07/2003CA2813048A1 Composition for use in treating patients suffering from movement disorder
08/07/2003CA2714295A1 Desaturase genes, enzymes encoded thereby, and uses thereof
08/07/2003CA2474908A1 Aggrecanase molecules
08/07/2003CA2474845A1 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions
08/07/2003CA2474813A1 A novel dosage form of l-methionine s-sulfoximine
08/07/2003CA2474788A1 Compositions and methods for modulating connexin hemichannels
08/07/2003CA2474689A1 Drugs ameliorating circadian rhythum disorder
08/07/2003CA2474649A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003CA2474434A1 Condensed heterocyclic compounds
08/07/2003CA2474306A1 Selective analgesic agents
08/07/2003CA2473987A1 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
08/07/2003CA2473803A1 Substituted indoles as alpha-1 agonists
08/07/2003CA2473457A1 Cotherapy with an oxazolidinone and a vitamin b
08/07/2003CA2473249A1 New corticosteroids
08/07/2003CA2473162A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003CA2473128A1 Genetic polymorphisms in the preprotachykinin gene
08/07/2003CA2466915A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor
08/07/2003CA2466228A1 Method for treating diseases with omega interferon
08/07/2003CA2463476A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
08/07/2003CA2443023A1 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/06/2003EP1333088A1 Paramyxovirus vectors for introducing foreign genes into skeletal muscle
08/06/2003EP1332372A2 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
08/06/2003EP1332363A1 Detection of neurodegenerative disorders
08/06/2003EP1332218A1 Differentiation-inducing substances
08/06/2003EP1332159A1 Process for the preparation of latent antithrombin iii
08/06/2003EP1332151A1 Pyranoside derivatives
08/06/2003EP1332149A1 Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase
08/06/2003EP1332147A1 Thieno[2,3-c isoquinolines for use as inhibitors of parp
08/06/2003EP1332146A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332138A1 Radiopharmaceuticals for diagnosing alzheimer's disease
08/06/2003EP1332136A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332133A1 Metabotropic glutamate receptor antagonists
08/06/2003EP1332132A2 Enamine derivatives as cell adhesion molecules
08/06/2003EP1332131A2 Acid derivatives useful as serine protease inhibitors
08/06/2003EP1332128A1 Benzamidine derivatives comprising a sulfate group serving as ltb4 antagonists
08/06/2003EP1332127A2 Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis
08/06/2003EP1331960A2 Device and method for the cessation of smoking
1 ... 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 ... 1833